A type of mutation that begins in bone marrow, not in the heart itself, is silently raising the risk of heart attacks and strokes for a large share of adults. These somatic mutations give rise to a condition called clonal hematopoiesis of indeterminate potential, or CHIP, in which a single blood-forming stem cell acquires a genetic change and spawns an outsized share of a person’s blood cells. Research published in The New England Journal of Medicine found that CHIP approximately doubles the risk of coronary heart disease, and a 2026 Nature paper has since shown that common lifestyle factors like sleep and exercise affect CHIP-driven inflammation differently depending on which gene is mutated.
How bone marrow mutations quietly fuel heart disease
CHIP does not produce symptoms on its own. The mutations accumulate with age in hematopoietic stem cells, and the resulting clones churn out white blood cells that carry the same genetic error. Those mutant immune cells migrate into artery walls, where they trigger chronic, low-grade inflammation that accelerates plaque buildup. The National Heart, Lung, and Blood Institute has described the process as a bone-deep contributor to heart disease, a phrase that captures how the danger originates far from the coronary arteries it eventually damages.
The foundational evidence comes from a study led by Siddhartha Jaiswal and colleagues, published in The New England Journal of Medicine, which analyzed whole-exome sequencing data from four large prospective cohorts. Carriers of CHIP mutations faced about twice the risk of coronary heart disease compared with people without the mutations. In mouse experiments from the same study, disrupting the Tet2 gene in hematopoietic cells accelerated atherosclerosis, providing a direct mechanistic link between a blood-cell mutation and artery disease.
That inflammatory pathway also aligns with findings from the CANTOS trial, a large randomized study published in The New England Journal of Medicine. CANTOS tested canakinumab, a drug that blocks the inflammatory cytokine IL-1 beta, in patients who had already suffered a heart attack and had elevated levels of high-sensitivity C-reactive protein. The trial demonstrated that lowering inflammation reduced recurrent cardiovascular events, supporting the broader idea that immune and inflammatory pathways, rather than cholesterol alone, can be primary drivers of cardiac risk.
In that context, CHIP looks less like an obscure genetic curiosity and more like a new entry on the list of modifiable cardiovascular drivers-albeit one that operates through the bone marrow. Instead of raising LDL cholesterol, CHIP amplifies the inflammatory tone of circulating immune cells. Those cells, particularly monocytes and macrophages, become more prone to secreting cytokines and to ingesting lipids, helping transform fatty streaks in arteries into complex, rupture-prone plaques.
Clinicians are only beginning to grapple with what to do about this. There is no approved therapy that directly targets CHIP clones, and current guidelines do not recommend routine screening. But the biology suggests that people with CHIP, especially those who already have coronary disease, might be particularly good candidates for aggressive risk-factor control and possibly for future anti-inflammatory drugs if those prove safe and effective in this population.
Sleep, exercise, and the mutation that changes everything
If CHIP drives heart risk through inflammation, can everyday habits dial that inflammation down? A 2026 study published in Nature tackled the question and produced a nuanced answer: it depends on which mutation a person carries. The research found that the effects of sleep and exercise on mutation-driven inflammation vary by CHIP mutation type and operate through local reprogramming of mutant macrophages lodged in blood vessel walls.
That distinction matters because the two most common CHIP driver genes, TET2 and DNMT3A, appear to respond differently to behavioral interventions. The Nature paper’s findings suggest that adults carrying TET2 mutations may experience a measurable reduction in arterial inflammation when they get adequate sleep and regular physical activity, while those with DNMT3A mutations may not benefit in the same way. The mechanism centers on how each mutation alters the inflammatory programming of macrophages once those cells embed themselves in vascular tissue. In other words, the same healthy habit could calm one person’s hidden inflammation while leaving another’s largely unchanged.
The study used animal models and imaging of vascular inflammation to show that, in TET2-mutant settings, improving sleep quality and increasing exercise reduced pro-inflammatory signaling in the vessel wall. By contrast, DNMT3A-mutant cells appeared more resistant to this environmental reprogramming, maintaining a higher baseline of inflammatory gene expression despite the same behavioral changes.
This gene-specific response opens a new line of inquiry: could serial imaging, such as PET-CT scans measuring aortic inflammation, eventually be used to track whether a sleep and exercise regimen is working for a given CHIP carrier? The hypothesis is plausible based on the Nature data, but no completed clinical trial has yet tested a standardized intervention with that kind of imaging endpoint in CHIP-positive adults. For now, the work mainly underscores that “lifestyle medicine” may not be one-size-fits-all at the molecular level.
Gaps in the evidence and what to watch next
Several questions remain open. No primary source in the current body of research supplies a precise count of how many adults in the United States or worldwide carry CHIP mutations. Population-based sequencing studies in cohorts like the UK Biobank and All of Us have identified CHIP carriers, but differences in variant-calling thresholds and sequencing depth make it difficult to settle on a single reliable prevalence figure. A methods paper published in Blood Advances detailed the technical challenges of curating CHIP calls from large whole-exome and whole-genome datasets, warning that noisy variant detection can inflate or deflate estimates.
The available research also lacks longitudinal outcome data linking specific CHIP mutations to conditions beyond atherosclerosis, such as myocarditis or pericarditis, in large enough numbers to draw firm conclusions. A JAMA Cardiology study explored that connection, but the cohort sizes and follow-up periods leave room for further investigation. Similarly, while CHIP is known to raise the risk of blood cancers like acute myeloid leukemia, the absolute annual progression risk is relatively low, and most carriers will never develop leukemia-an important nuance that large registries are still refining.
Another gap involves screening and management. There is no consensus on whether asymptomatic adults should undergo genetic testing for CHIP, and most sequencing that uncovers these mutations today is done for other reasons, such as cancer workups or research participation. Even when CHIP is found, clinicians lack evidence-based algorithms to decide how often to monitor blood counts, when to refer to hematology, or whether to alter standard cardiovascular prevention strategies beyond what is already recommended for age and overall risk profile.
Drug development is only beginning to catch up. The CANTOS findings revived interest in anti-inflammatory strategies for heart disease, but canakinumab itself is expensive and carries infection risks, making it unlikely to become a broad prevention tool for CHIP carriers. Researchers are exploring more targeted approaches that might blunt the inflammatory output of mutant clones without suppressing the entire immune system, yet these remain early-stage concepts rather than therapies ready for routine care.
For readers, the practical takeaway is both reassuring and forward-looking. Most people with CHIP will never know they have it, and current guidelines do not call for routine testing. The core heart-health advice-do not smoke, control blood pressure and cholesterol, stay active, and prioritize sleep-still applies regardless of mutation status and is unlikely to change. What the emerging science adds is an explanation for why those habits matter so much and why, in the future, doctors may fine-tune prevention plans based on which bone marrow mutations a person carries.
As larger cohorts mature and more CHIP carriers are followed over time, researchers expect clearer answers on who is at highest risk, which mutations respond best to behavioral or pharmacologic interventions, and whether screening should ever become part of standard cardiovascular care. Until then, CHIP serves as a reminder that heart disease can begin far from the heart-and that the conversation about prevention increasingly starts in the bone marrow.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
